anti
To sponsor this category, click here | subscribe to this category RSS

Home » Archives for anti

Gene Mutation Offers Clues to Tamoxifen-Blood Clot Link (HealthDay)

Thursday, June 17th, 2010

HealthDay – THURSDAY, June 17 (HealthDay News) — Researchers have identified a gene mutation that increases the risk of blood clots in women taking the anti-cancer drug tamoxifen after surgery for early-stage breast cancer.

Posted in: headlines | 0 Comments »
Read the full story
No Image

The Problem With Research on Aging

Thursday, March 25th, 2010

Nature has a review of a new book on the anti-aging field, Eternity Soup by Greg Critser, and I found this part very instructive.

Posted in: Clinical Trials | 0 Comments »
Read the full story

Angiogenesis Inhibitors: Helping or Hurting?

Thursday, May 7th, 2009

Now, here’s something to think about: can angiogenesis inhibitors, the famous class of tumor-starving cancer drugs, actually make some kinds of cancer worse?

Posted in: Clinical Trials | 0 Comments »
Read the full story

Into the Clinic. And Right Back Out.

Wednesday, May 6th, 2009

Here’s a good example of why all of us in the industry tiptoe into Phase I trials, the first-in-man studies. A company called SGX, recently acquired by Eli Lilly, has been developing a kinase inhibitor (SGX523) targeting the enzyme cMET.

Posted in: Clinical Trials | 0 Comments »
Read the full story

Farewell to ACAT, and to Lots of Time and Money, Too

Tuesday, May 5th, 2009

Back when I joined the first drug company I ever worked for, the group in the lab next door was working on an enzyme called ACAT, acyl CoA:cholesterol acyltranferase. It’s the main producer of cholesterol esters in cells, and is especially known to be active in the production of foam cells in atherosclerosis. It had already been a drug target for some years before I first heard about it, and has remained one.

Posted in: Clinical Trials | 0 Comments »
Read the full story